EFFICACY OF FLUCONAZOLE IN THE TREATMENT OF SYSTEMIC FUNGAL-INFECTIONS

被引:33
作者
MILATOVIC, D
VOSS, A
机构
[1] Department of Clinical Microbiology, Technical University of Munich, Munich 80, 8000, Trogerstr
关键词
D O I
10.1007/BF01961853
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The efficacy of fluconazole in the treatment of systemic fungal infections was evaluated in an open non-comparative trial. A total of 48 patients with proven or suspected fungal infections were enrolled in 40 of whom efficacy was evaluable. Candida albicans accounted for 90 % of the infections. Candida parapsilosis, Candida glabrata, Histoplasma capsulatum and Aspergillus fumigatus caused the infection in one case each. Fluconazole was administered at a dosage of 200-400 mg daily for a mean duration of 15 days. Fluconazole treatment was successful in 53 % of the patients. In patients with proven or probable Candida albicans infections a clinical and mycological response was achieved in 62 % and 65 %, respectively. In 11 patients elevation of liver enzymes was considered to be possibly related to fluconazole treatment; modification of treatment was not necessary in any case. Fluconazole was found to be a well tolerated and effective agent for the treatment of systemic Candida albicans infections.
引用
收藏
页码:395 / 402
页数:8
相关论文
共 24 条
[1]   FLUCONAZOLE PENETRATION INTO CEREBROSPINAL-FLUID - IMPLICATIONS FOR TREATING FUNGAL-INFECTIONS OF THE CENTRAL NERVOUS-SYSTEM [J].
ARNDT, CAS ;
WALSH, TJ ;
MCCULLY, CL ;
BALIS, FM ;
PIZZO, PA ;
POPLACK, DG .
JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (01) :178-180
[2]  
BRAMMER KW, 1988, EUR J CLIN MICROBIOL, V7, P364, DOI 10.1007/BF01962338
[3]  
DUPONT B, 1988, J MED VET MYCOL, V26, P67
[4]   CRYPTOCOCCAL MENINGITIS AND FLUCONAZOLE [J].
DUPONT, B ;
DROUHET, E .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (05) :778-778
[5]   AMPHOTERICIN-B OR KETOCONAZOLE THERAPY OF FUNGAL-INFECTIONS IN NEUTROPENIC CANCER-PATIENTS [J].
FAINSTEIN, V ;
BODEY, GP ;
ELTING, L ;
MAKSYMIUK, A ;
KEATING, M ;
MCCREDIE, KB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (01) :11-15
[6]   A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
GOODMAN, JL ;
WINSTON, DJ ;
GREENFIELD, RA ;
CHANDRASEKAR, PH ;
FOX, B ;
KAIZER, H ;
SHADDUCK, RK ;
SHEA, TC ;
STIFF, P ;
FRIEDMAN, DJ ;
POWDERLY, WG ;
SILBER, JL ;
HOROWITZ, H ;
LICHTIN, A ;
WOLFF, SN ;
MANGAN, KF ;
SILVER, SM ;
WEISDORF, D ;
HO, WG ;
GILBERT, G ;
BUELL, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :845-851
[7]  
Graybill J. R., 1987, Recent trends in the discovery, development and evaluation of antifungal agents., P113
[8]  
HORN R, 1985, REV INFECT DIS, V7, P646
[9]   ACTION OF FLUCONAZOLE (UK-49,858) IN RELATION TO OTHER SYSTEMIC ANTIFUNGAL AZOLES [J].
HUGHES, CE ;
BEGGS, WH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 19 (02) :171-174
[10]   PHARMACOKINETIC EVALUATION OF UK-49,858, A METABOLICALLY STABLE TRIAZOLE ANTIFUNGAL DRUG, IN ANIMALS AND HUMANS [J].
HUMPHREY, MJ ;
JEVONS, S ;
TARBIT, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (05) :648-653